Progenics Pharmaceuticals (FRA:PGP) Additional Paid-In Capital : €658.96 Mil(As of Mar. 2020)

View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Additional Paid-In Capital?

Progenics Pharmaceuticals's quarterly additional paid-in capital declined from Sep. 2019 (€658.62 Mil) to Dec. 2019 (€654.38 Mil) but then increased from Dec. 2019 (€654.38 Mil) to Mar. 2020 (€658.96 Mil).

Progenics Pharmaceuticals's annual additional paid-in capital increased from Dec. 2017 (€515.31 Mil) to Dec. 2018 (€626.74 Mil) and increased from Dec. 2018 (€626.74 Mil) to Dec. 2019 (€654.38 Mil).

Progenics Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Progenics Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Additional Paid-In Capital Chart

Progenics Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Additional Paid-In Capital

Get a 7-Day Free Trial

545.76

566.97

515.31

626.74

654.38

Progenics Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Additional Paid-In Capital	Get a 7-Day Free Trial															631.98	640.76	658.62	654.38	658.96

Progenics Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Progenics Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Progenics Pharmaceuticals (FRA:PGP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (FRA:PGP) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007

Website

http://www.progenics.com

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Progenics Pharmaceuticals (FRA:PGP) Headlines

From GuruFocus

PGP Statement on SEC Settlement

By sperokesalga sperokesalga • 06-16-2023